hCG is one of 72 small molecule programs targeting Luteal Phase Insufficiency. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
72 competitors in Polycystic Ovary Syndrome
Victoza
Avandia
Ozempic
Daliresp
Onglyza
Calciferol
Gynorest
Tradjenta
Andriol
Acetadote
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details